Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


LVAD Companies Address Thrombosis Fears Raised In NEJM Report

This article was originally published in The Gray Sheet

Executive Summary

The CEOs of Thoratec and HeartWare addressed the recent highly publicized report on the risk of LVAD thrombosis at the J.P. Morgan Healthcare Conference.

You may also be interested in...

Regulatory News Briefs

A new refuse-to-accept guidance; FDA finalizes classification decisions; and the agency awards an emergency authorization for a new rapid Ebola assay.

Heart Failure: Next-Gen VADs Fuel Optimism Amid Challenges

Although near-term challenges have slowed growth in the market for left ventricular assist devices (LVADs), companies are developing new, less invasive VADs with improved pump designs to further improve patient outcomes and allow for a wider application of the therapy in treating heart failure. These next-generation VADs are fueling long-term optimism in the market for mechanical circulatory support, which remains one of the more attractive opportunities in the cardiovascular space.

Thoratec Says Thrombosis Fears Are Immaterial So Far, But Remains Vigilant

Thoratec says that the recent article in the New England Journal of Medicine describing surprisingly high rates of pump thrombosis in left-ventricular assist devices may have short-term sales implications, but they will minimize over time. The company says it is working with clinical centers on best practices to avoid thrombosis.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts